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Abstract: 
Non-union fractures and large bone defects are significant targets for 
osteochondral tissue engineering strategies. A major hurdle in the use of 
these therapies is the foreign body response of the host. Herein, we report 
the development of a bone tissue engineering scaffold with the ability to 
release anti-inflammatory drugs, in the hope of evading this response. 
Porous, sintered scaffolds composed of poly(DL-lactic acid-co-glycolic acid) 
(PLGA) and poly(ethylene glycol) (PEG) were prepared with and 
without  the anti-inflammatory drug diclofenac sodium. Analysis of drug 
release over time demonstrated a profile suitable for the treatment of 
acute inflammation with approximately 80% of drug released over the first 
4 days and a subsequent release of around 0.2% per day. Effect of drug 
release was monitored using an in vitro osteoblast inflammation model, 
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comprised of mouse primary calvarial osteoblasts stimulated with 
proinflammatory cytokines interleukin-1β (IL-1β), tumour necrosis factor-α 
(TNF-α) and interferon-γ (IFN-γ). Levels of inflammation were monitored 
by cell viability and cellular production of nitric oxide (NO) and 
prostaglandin E2 (PGE2). The osteoblast inflammation model revealed that 
proinflammatory cytokine addition to the medium reduced cell viability to 
33%, but the release of diclofenac sodium from scaffolds inhibited this 
effect with a final cell viability of approximately 70%. However, releasing 
diclofenac sodium at high concentrations had a toxic effect on the cells. 
Proinflammatory cytokine addition led to increased NO and PGE2 
production; diclofenac sodium releasing scaffolds inhibited NO release by 
approximately 64% and PGE2 production by approximately 52%, when the 
scaffold was loaded with the optimal concentration of drug. These 
observations demonstrate the potential use of PLGA/PEG scaffolds for 
localised delivery of anti-inflammatory drugs in bone tissue engineering 
applications. 
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Abstract 
Non-union fractures and large bone defects are significant targets for osteochondral 
tissue engineering strategies. A major hurdle in the use of these therapies is the 
foreign body response of the host. Herein, we report the development of a bone 
tissue engineering scaffold with the ability to release anti-inflammatory drugs, in the 
hope of evading this response. Porous, sintered scaffolds composed of poly(DL-
lactic acid-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) were prepared 
with and without  the anti-inflammatory drug diclofenac sodium. Analysis of drug 
release over time demonstrated a profile suitable for the treatment of acute 
inflammation with approximately 80% of drug released over the first 4 days and a 
subsequent release of around 0.2% per day. Effect of drug release was monitored 
using an in vitro osteoblast inflammation model, comprised of mouse primary 
calvarial osteoblasts stimulated with proinflammatory cytokines interleukin-1β (IL-
1β), tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Levels of 
inflammation were monitored by cell viability and cellular production of nitric oxide 
(NO) and prostaglandin E2 (PGE2). The osteoblast inflammation model revealed that 
proinflammatory cytokine addition to the medium reduced cell viability to 33%, but 
the release of diclofenac sodium from scaffolds inhibited this effect with a final cell 
viability of approximately 70%. However, releasing diclofenac sodium at high 
concentrations had a toxic effect on the cells. Proinflammatory cytokine addition led 
to increased NO and PGE2 production; diclofenac sodium releasing scaffolds 
inhibited NO release by approximately 64% and PGE2 production by approximately 
52%, when the scaffold was loaded with the optimal concentration of drug. These 
observations demonstrate the potential use of PLGA/PEG scaffolds for localised 
delivery of anti-inflammatory drugs in bone tissue engineering applications.    
Page 4 of 39
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/ Not for Distribution
Introduction 
Non-union fractures, large bone defects and diseases such as rheumatoid arthritis 
are significant targets for osteochondral tissue engineering strategies. Under normal 
circumstances, bone has a significant capacity for regeneration and is one of the few 
tissues that can heal without a scar (1). Fracture healing consists of three stages: 
inflammation; repair; and remodelling. The initial inflammatory phase plays a critical 
role in healing and many of the processes that occur at this stage determine the 
outcome of bone repair. Within 24 hours of bone injury, neutrophils and 
macrophages will have migrated into the wound site and levels of tumour necrosis 
factor α (TNF-α), interleukin 1 (IL-1), interferon-γ (IFN-γ) and interleukin 6 (IL-6) will 
reach their peak (2-4). These cytokines lead to recruitment of additional cells 
involved in inflammation, promotion of angiogenesis and mesenchymal stem cell 
(MSC) differentiation. The acute inflammatory phase usually lasts for one week, after 
which levels of inflammatory mediators return to baseline (4-7). During the 
subsequent remodelling phase of fracture healing, the expression levels of cytokines 
such as IL-1, TNF-α and IL-6 rise once more, but do not reach the levels of the acute 
inflammatory response (8).  
Due to the complexity of processes involved in fracture healing, there are clinical 
indications where inflammation fails to resolve the problem, such as inflammatory 
diseases, severe body reactions and non-union fractures.  The current “gold-
standard” treatment for non-union fractures and defects is autologous bone grafts. 
However, such grafts are limited due to availability and have disadvantages such as 
donor site morbidity, additional surgery and chronic pain. This has inspired the 
development of tissue engineered bone substitutes. These bone substitutes are 
required to provide mechanical stability, support cell growth, and aid bone 
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regeneration. A common disadvantage of any tissue-engineered therapy is 
inflammation and foreign body response, upon implantation and degradation (9). 
Thus, the adaptation of a bone tissue engineering scaffold that provides release of 
anti-inflammatory mediators could potentially enhance the properties of the therapy 
and improve success rates upon implantation (10, 11). 
In this study, we investigate release of the anti-inflammatory drug diclofenac sodium 
from porous poly(DL-lactic acid-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) 
microparticle-based scaffolds. Non-steroidal anti-inflammatory drugs (NSAIDs), such 
as diclofenac, have systemic treatment side-effects of gastrointestinal ulceration and 
bleeding, hepato-renal dysfunction and skin reactions (12). Local delivery of this drug 
via scaffolds offers a method of bypassing the side effects of systemic drug 
treatment. The properties of the PLGA/PEG scaffolds have been reported and are 
established as suitable for bone repair (13-15). The scaffold has demonstrated 
efficacy in the sustained release of growth factors, antibiotics and chemotherapeutics 
(14, 16, 17). The potential exploitation of the scaffold as an anti-inflammatory drug 
delivery vehicle will enhance the existing osteoinductive properties of the PLGA/PEG 
scaffolds in bone repair. The scaffolds are manufactured from PLGA/PEG 
microparticles that form a paste when mixed with a carrier solution. This paste can 
be easily injected or pasted into the area of interest and subsequently solidifies at 
body temperature forming a porous scaffold.  
Current validation methods for testing the properties and effectiveness of anti-
inflammatory drugs released as part of  tissue engineering studies are predominantly 
in vivo animal models (18-20). Current in vitro models are few and far between but 
involve the use of tissue slices (21-23). In this study, a simple in vitro calvarial 
osteoblast inflammation model is created using the proinflammatory cytokines IL-1β, 
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TNF-α and IFN-γ. This model is then used to evaluate the effects of anti-
inflammatory drug release from the PLGA/PEG scaffolds. Common markers of the 
effects of proinflammatory cytokines on osteoblasts, such as viability, nitric oxide 
(NO) production and prostaglandin E2 (PGE2) production are used to assess the 
efficacy of drug release (24, 25). The in vitro model is not intended to replace animal 
models, but offers a simple initial step to gather information about effectiveness of 
drug release from scaffolds.  
 
Materials and Methods 
Extraction and culture of primary calvarial osteoblasts 
Primary calvarial osteoblasts were obtained from 1-3 day old CD1 mouse calvaria by 
sequential enzymatic digestion. Calvaria were dissected and digested in a solution of 
1.4 mg/mL collagenase type IA (Sigma Aldrich, Poole, UK) and 0.5 mg/mL trypsin II 
S (Sigma). Cells released during the first 2 digestions (10 min) were discarded, and 
populations of cells from the next 3 digestions (20 min) were plated in tissue culture 
flasks at a density of 6.6 x 103 cells/cm2. Cells were cultured in minimum essential 
medium-α (αMEM, Lonza, Belgium), containing 10% FBS (Sigma), 2 mM L-
Glutamine (Sigma), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma). For 
experimentation, cells were passaged via trypsin/EDTA, plated at a density of 10,600 
cells/cm2 and allowed to adhere overnight in well plates. Medium was subsequently 
supplemented with 50 mM β-Glycerophosphate (BGP, Sigma) and 50 µg/mL 
ascorbate 2-phosphate (Sigma), to induce osteogenic differentiation. 
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Proinflammatory Cytokine Treatment 
Recombinant human IL-1β, human TNF-α and mouse IFN-γ (R&D Systems), were 
added to the culture medium at a concentration of 0.25 ng/mL, 2.5 ng/mL and 25 
ng/mL respectively, unless otherwise stated.  
 
MTS Viability Assay 
A tetrazolium salt assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] (Promega, UK, CellTiter 96® 
AQueous One Solution Cell Proliferation Assay) was performed as per the 
manufacturer’s protocol. Briefly, 20 µL MTS solution was added to 100 µL culture 
media. After incubation for 1 hr at 37°C, the absorbance of each well was measured 
at 490 nm using plate reader. 
 
Nitric Oxide and Prostaglandin E2 Production 
Nitrite in culture medium was measured as an estimation of NO production, using the 
Griess Reagent System (Promega). Nitrite concentration within culture medium 
samples was determined by adding 1% sulphanilamide in 5% phosphoric acid, 
incubating for 5 minutes before adding 0.1% N-(1 
napthyl)ethylenediaminedihydrochloride (NED) in water. Absorbance was read after 
5 minutes room temperature incubation at 540 nm with wavelength correction at 690 
nm.  
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Prostaglandin E2 (PGE2) concentration within culture medium was determined by 
enzyme immunoassay (EIA) using a commercially available kit (R&D Systems). 
Briefly, a competitive binding EIA was performed on 3-fold diluted samples. Optical 
absorbance was read at 450 nm with correction at 570 nm.  
 
Immunocytochemistry 
After treatment with diclofenac sodium and/or proinflammatory cytokines, cell 
monolayers were fixed with a 4% solution of paraformaldehyde (Sigma). Cells were 
permeabilized with 0.1% (v/v) Triton X-100 (Sigma) for 45 minutes and washed with 
PBS. Nonspecific binding was blocked by incubating in 3% donkey serum (Sigma) 
for 30 minutes. Samples were incubated with primary antibodies at 4°C overnight.  
PBS washes were performed and samples incubated with secondary antibodies 
(donkey Alexa-Fluor-488 or 546, Invitrogen) for 1 hour at room temperature. Nuclear 
counterstaining with Hoechst 33258 was performed.  Primary antibodies were goat 
anti-osteopontin (R&D Systems), goat anti-osteocalcin (Millipore, UK), rabbit anti-
collagen-I (Millipore, UK) and goat anti-cadherin-1 (R&D Systems). Fluorescent 
images were captured and processed using a Leica DM-IRB inverted microscope 
and Volocity imaging software (Improvision, Coventry, UK). 
 
PLGA/PEG Particle Production 
Thermosensitive particles were manufactured from 53kDa PDLLGA (85:15 DLG 4CA) 
(Evonik Industries, USA) and PEG 400 (Sigma Aldrich, UK) as previously described 
(13). Briefly, the PLGA and PEG were blended at a ratio of 93.5:6.5 (w/v), at 80-90°C 
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on a hotplate and allowed to cool. Polymer blend sheets were ground into particles in 
a bench-top mill (Krups Mill F203) and sieved to obtain a 100-200 µm particle size 
fraction. 
 
Diclofenac Sodium Loaded PLGA/PEG Scaffold Manufacture 
Scaffolds were prepared in PTFE moulds producing cylindrical scaffolds of 12 mm 
length and 6 mm diameter. PLGA/PEG particles were mixed manually at a ratio of 
1:0.6, particles to PBS carrier solution. Diclofenac sodium (Sigma) loaded scaffolds 
were produced by mixing particles with PBS containing diclofenac sodium. The 
microparticle/PBS paste was packed into the moulds. Solid scaffolds were produced 
after sintering at 37°C for 3 hours. 
 
Scanning Electron Microscopy 
Scaffolds were cut in half to allow the centre to be imaged. Cut scaffolds were 
mounted on aluminium stubs and were sputter-coated with gold at an argon current 
rate of 30 mA for 3 min. The structural morphology of the scaffolds was examined 
using a SEM (JEOL JSM-6060LV) at 10 kV. 
 
Measurement of drug release from PLGA/PEG Scaffolds 
After sintering, scaffolds were removed from moulds and placed into phenol red-free 
αMEM (Invitrogen, UK), with 100 U/mL penicillin and 100 µg/mL streptomycin, and 
incubated at 37°C. Release medium was removed for drug concentration 
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measurements, and fresh release medium added. Drug release was measured by 
ultraviolet-visible (UV-Vis) spectrophotometry at 276 nm. Concentrations of drug 
within the medium were determined using calibration curves. 
 
Calvarial osteoblast inflammation model 
Osteoblasts were cultured in monolayer for 14 days in osteogenic medium. UV-
sterilised scaffolds were placed in transwells above the cell monolayer with medium 
added to cover scaffold. During diclofenac-release experiments, medium was 
changed to phenol-red free αMEM containing 10% FBS, 100 U/mL penicillin and 100 
µg/mL streptomycin, 2 mM L-Glutamine, 50 mM BGP and 50 µg/mL ascorbate 2-
phosphate. In experimental groups stimulated with cytokines, initial concentration 
was 1 ng/mL IL-1β, 10 ng/mL TNF-α and 100 ng/mL IFN-γ. Medium was collected 
after 24 hours and replaced with medium containing 0.25 ng/mL IL-1β, 2.5 ng/mL 
TNF-α and 2.5 ng/mL IFN-γ. This medium was collected after a further 24 hours and 
replaced with 0.0625 ng/mL IL-1β, 0.625 ng/mL TNF-α and 6.25 ng/mL IFN-γ. This 
medium was left for a further 5 days until experiment end at day 7. 
 
Live/Dead™ Viability Assay 
Live/Dead™ viability/cytotoxicity assay (Invitrogen) was performed on the cell 
monolayers at the end of scaffold release experiments (day 7). Cell monolayers were 
incubated with a solution of 2 µM calcein AM and 4 µM EthD-1 in PBS for 30 minutes 
at room temperature. Monolayers were imaged using an inverted fluorescent 
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microscope. Live/dead quantification was performed using ImageJ version 1.43U 
(NIH, USA). 
 
Statistical Analysis 
Statistical significance between groups was analyzed using PASW Statistics 18.0.3 
software. Two groups were compared by unpaired Student’s T-Test, multiple groups 
by one-way ANOVA.   
 
Results 
Effect of diclofenac sodium and IL-1β, TNF-α and IFN-γ on the in vitro 
responses of primary osteoblasts 
The effects of diclofenac sodium on proinflammatory cytokine treated osteoblasts 
were assessed prior to release from scaffolds. Primary osteoblasts were cultured in 
osteogenic medium for 14 days before cytokines and diclofenac added. Cell viability 
was monitored over the following 21 days (figure 1A). Adding diclofenac sodium 
caused a reduction in viability over the 21 days, showing slight toxicity to the cells. 
The addition of IL-1β, TNF-α and IFN-γ caused a significant drop in viability over the 
21 day period, to 32% (±14%) compared with the control. The addition of diclofenac 
with cytokines inhibited the cytokine-induced cell death, with a viability of 92% 
(±11%) at day 14 and 62% (±2.5%) at day 21.   
Figures 1B and 1C show cumulative production of nitrite and PGE2 respectively, by 
primary osteoblasts, in the presence of diclofenac sodium and/or proinflammatory 
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cytokines. Addition of IL-1β, TNF-α and IFN-γ to the medium caused significantly 
increased nitrite and PGE2 production, compared to control osteogenic medium and 
100 µM diclofenac. Nitrite accumulation in groups treated with both cytokines and 
diclofenac was significantly lower across all timepoints than those with cytokines 
alone. However, nitrite levels in this group remained significantly higher than the 
controls. Diclofenac sodium was effective in inhibiting PGE2 production. 
Accumulated PGE2 concentration in the group treated with cytokines and diclofenac 
remained similar to controls across all timepoints. Diclofenac sodium was shown to 
maintain effectiveness as an NSAID in this model across a 27-day time period. 
Figure 1D and 1E show the effect of the cytokines and diclofenac on primary 
osteoblast differentiation, with staining for osteopontin (OPN) with osteocalcin (OCN) 
(1D) and collagen-I with cadherin-11 (1E). Osteoblasts were cultured for 14 days in 
osteogenic medium before the addition of cytokines and diclofenac. Staining was 
subsequently performed on day 21. Compared to osteogenic medium, treatment with 
proinflammatory cytokines produced smaller and less abundant nodules with dense 
OPN staining, little OCN and more disperse collagen-I staining. Hoechst staining 
showed that there were fewer cells within nodules relative to osteogenic controls. In 
cells treated with proinflammatory cytokines and diclofenac, the nodules were of a 
similar size and cell density to the controls and denser staining for osteocalcin, 
collagen-1 and cadherin-11 was seen than in those treated with cytokines alone. 
 
Diclofenac sodium release from PLGA/PEG scaffolds 
The PLGA/PEG scaffolds had a porous microstructure (figure 2A) formed by 
particles fusing together at 37°C. When unconstrained, scaffolds showed a small 
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amount of swelling after being placed in medium for drug release (figure 2B). In later 
studies, with release onto cell monolayers, scaffolds were constrained by transwells 
and release remained unchanged (data not shown). 
The release of diclofenac sodium from the PLGA/PEG scaffolds over time was 
assessed by UV spectrophotometry. The cumulative mass drug release can be seen 
in figure 3A, and converted to percentage of initial loading in figure 3B. Scaffolds 
were loaded with different concentrations of diclofenac to determine effect of initial 
drug loading on release profile. All scaffolds showed a similar release profile 
regardless of original loading, with an initial burst release phase of 55-62% over the 
first 4 hours, followed by approximately 20% release by day 1, decreasing to 3% 
release by day 2. After day 4, release reached a steady state of around 0.2% per 
day. From day 42, this rate increased to about 0.3% per day as the scaffolds started 
to degrade. By day 68, the scaffolds had degraded and average of 96% (±3%) of the 
loaded drug had been released per scaffold. 
 
Viability of primary calvarial osteoblasts after diclofenac sodium release from 
PLGA/PEG scaffolds 
Diclofenac releasing scaffolds were placed in transwells above osteoblast 
monolayers and culture medium with and without IL-1β, TNF-α and IFN-γ added. 
Live/dead images were taken of the primary osteoblast monolayers after 7 days drug 
release from the scaffolds (figure 4A) and images quantified (figure 4B and 4C). In 
osteogenic medium with no scaffold and 0 µg, 300 µg and 650 µg drug-loaded 
scaffolds, there were very few dead cells. An initial load of 1000 µg caused a large 
increase in the number of dead cells and lowered the percentage viability to below 
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20%, indicating a toxic burst-release. In medium containing IL-1β, TNF-α and IFN-γ, 
with no scaffold and 0 µg scaffolds, there was a large fall in cell viability, to 33% and 
23% respectively. Release of diclofenac from the 300 µg and 650 µg scaffolds 
improved cell viability in cytokine medium to 76% and 68% correspondingly. The 
1000 µg loaded scaffold in cytokine medium showed an enhanced negative effect 
with significantly less total cells and a viability of 3%. 
 
Effect of diclofenac sodium-releasing PLGA/PEG scaffolds on NO production 
in the osteoblast inflammation model 
Levels of nitrite in the medium were measured after day 1, day 2 and at day 7, to 
estimate NO production (figure 5). In osteogenic control medium with and without 
scaffolds, there was minimal NO production. When proinflammatory cytokines were 
present, the control (no scaffold) and the 0 µg scaffold showed significantly 
increased NO, at all timepoints. The 300 µg diclofenac releasing scaffolds showed 
no significant NO production on day 1, but day 2 and day 7 levels were significantly 
increased. The 650 µg scaffolds showed inhibition of NO production at all timepoints, 
although by day 7, concentrations were also increased significantly higher than no 
cytokine control. Scaffolds releasing 1000 µg diclofenac, showed low nitrite 
production across all timepoints, but low levels can be correlated with low cell 
viability. Cumulative nitrite production across the 7 days (figure 5B) shows that the 
650 µg loaded scaffolds significantly inhibited cytokine-induced NO production, with 
a reduction of approximately 64%, compared with the 0 µg scaffold in cytokine 
medium. 
 
Page 15 of 39
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/ Not for Distribution
Effect of diclofenac sodium-releasing PLGA/PEG scaffolds on PGE2 
production in the osteoblast inflammation model 
Concentration of PGE2 in the culture medium was measured on day 1, day 2 and 
day 7 (figure 6). PGE2 concentration across all groups, at all timepoints can be seen 
in figure 6A. When all groups are evaluated on the same graph, the “no scaffold” 
experimental group in cytokine medium shows a very large amount of PGE2 
production, skewing the data; this can also be seen in the cumulative data (figure 
6B). It was expected that similar levels of PGE2 would be produced by cells with 0 µg 
scaffolds, but this was not observed when assaying the medium. This effect could be 
attributed to either some of the PGE2 or proinflammatory cytokines adsorbing to the 
scaffold and therefore not remaining soluble in the medium, causing variation in 
results between those with the scaffold present and those without. However, figure 
6A does show a trend of increased PGE2 in the 0 µg scaffold on day 1 and day 2, 
compared to the 300 µg, 650 µg and 1000 µg diclofenac-releasing scaffolds, 
indicating some inhibition of cytokine-induced PGE2 by the presence of diclofenac. 
To get a more valuable understanding of how the scaffolds are affecting PGE2 
response, cumulative results excluding the “no scaffold” controls can be found in the 
inset of figure 6B. This shows that at all timepoints, the 0 µg scaffold showed 
increased PGE2 production in proinflammatory cytokine medium compared to control 
osteogenic medium. Cumulative PGE2 concentration in the medium until day 7 
showed that all diclofenac sodium loaded scaffolds, showed significant inhibition of 
cytokine-induced PGE2 production, with a reduction of 51.9% compared to the 0 µg 
scaffold in cytokine medium. 
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Discussion 
A major hurdle in the use of tissue-engineered therapies is the foreign body reaction 
of the host, associated with the implantation of the therapy. The aim of this study 
was the examination of PLGA/PEG scaffolds as a release vehicle for anti-
inflammatory drugs, with the eventual aim of evading the foreign body response in 
vivo. Diclofenac sodium was chosen as the drug of choice to test this system for 
several reasons: NSAIDs show appealing properties as an anti-inflammatory in bone 
treatment; good solubility in water; stability over time; successful results in both 
PGE2 and nitrite inhibition during in vitro tests; and finally, available literature 
describing release of diclofenac via various techniques (26-28). 
PGE2 and NO are important inflammatory mediators produced by osteoblasts in 
response to proinflammatory cytokines, and can be used to monitor levels of 
inflammation (24, 25, 29). The major mode of action of NSAIDs, such as diclofenac, 
is inhibition of PGE2 production through the cyclooxygenase-2 (COX-2) pathway (30, 
31). COX-2 is an inducible enzyme, generated in response to proinflammatory 
cytokine signalling, particularly IL-1 and TNF-α, leading to significantly increased 
production of PGE2 (32). The production of prostaglandins, such as PGE2, leads to 
the initial recruitment of neutrophils and subsequent recruitment of  macrophages 
(33). The release of diclofenac from a scaffold would potentially lead to less 
neutrophils and macrophages at the injury site, decreasing the acute inflammatory 
response that leads to pain, swelling and rejection. In some tissues this would lead 
to poor regeneration, however in bone, an absence of neutrophils and macrophages 
may not adversely affect tissue repair (34, 35). Macrophages have different 
phenotypes depending on the local tissue environment; the classically activated M1 
phenotype is present during acute inflammation and is linked to upregulation of 
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proinflammatory cytokines and enzymes such as inducible nitric oxide synthase 
(iNOS). During tissue regeneration, macrophages transition to an anti-inflammatory 
M2 phenotype that plays a role in dampening inflammation by the production of anti-
inflammatory cytokines such as IL-10 and IL-1ra (36, 37). The COX-2 pathway has 
been linked with the transition of M1 macrophages into M2 phenotypes, and thus 
treatment with diclofenac may cause a delay in the transition of M1 macrophages 
(38, 39). However in this system, effective anti-inflammatory release would only 
occur during the initial inflammatory stage and this transient exposure may not be 
enough to delay subsequent regeneration. 
In this study, diclofenac sodium successfully inhibited all cytokine-induced production 
of PGE2 in initial long-term cell monolayer tests. Inhibition of PGE2 production was 
also seen when diclofenac was released from scaffolds, although results were 
hampered by potential adsorption of PGE2 to the scaffold. Despite the success in 
this model, the complete inhibition of PGE2, and therefore COX-2, by an NSAID may  
not be completely desirable, as COX-2 plays a role in bone regeneration and fracture 
healing (40-42). In consideration of this, the drug diclofenac may not be optimal for 
this purpose but in future the system could be adapted for release of anti-
inflammatory drugs with alternative mechanisms of action. It is crucial to maintain the 
correct balance between effective anti-inflammatory function to prevent foreign body 
reaction, and the ability of the scaffold to regenerate bone, for this system to be 
successful. 
The ability of NSAIDs to inhibit NO production is not as well recognized, but did 
occur to a certain degree in this study, in initial long-term studies and during 
diclofenac release from scaffolds. This result is not unexpected as NSAIDs have 
been shown to inhibit iNOS activity, which leads to inflammation induced NO 
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production (43, 44). This process does not cause complete inhibition of NO 
production, and unlike the mode of action of anti-inflammatory glucocorticoids, is not 
caused by inhibition of iNOS mRNA (45). The diclofenac sodium results in this study 
show partial inhibition of NO production, in agreement with this statement. 
Interactions have previously been shown to exist between the COX and iNOS 
pathways in a number of cells, including osteoblasts (46-49); however the inhibitory 
effects of NSAIDs on NO production have been shown to be both COX-dependent 
and COX-independent (44, 48). Development and validation of the simple osteoblast 
inflammation model, led to the development of a tissue engineered drug release 
system. The injectable PLGA/PEG scaffold formulation has previously been reported 
and its suitability for bone tissue engineering has been demonstrated (13-15). The 
scaffolds were prepared from PLGA/PEG particles that form a paste when mixed 
with a carrier solution, in this case containing diclofenac. The paste hardens into a 
solid, porous scaffold when sintered at 37°C, due to temperature-induced PEG-
leaching (13). During the sintering process the diclofenac sodium in the carrier, most 
likely becomes adsorbed or absorbed within the particles and therefore becomes 
physically entrapped within the pores of the resulting scaffold structure. Drug release 
in this system is uncontrolled, occurring via diffusion through the pores; release 
therefore depends upon drug properties and interaction between the drug and 
polymer. In this study, release consisted of a large burst within the first few hours 
due to drug molecules adsorbed to the surface of the scaffold immediately releasing 
into the medium. In some cases, this would be considered an undesirable effect, but 
in the case of in vivo inflammation, this burst release of anti-inflammatory drug 
correlates with an influx of proinflammatory cytokines upon implantation of the 
scaffold. After the burst, drug release slowed rapidly. From day 1 to day 4, release 
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can be explained by diffusion of drug through water-filled pores. From day 4, release 
slowed substantially, but followed an almost first-order release profile, as the 
remaining drug found a way through the scaffold, diffusing into the medium. 
Initial loading of the drug within the scaffold had little effect on the release profile and 
consistency of release between batches of scaffolds correlated well. The length of 
time over which the majority of the diclofenac was released was about 6 days. This 
is in keeping with other tissue engineered anti-inflammatory release strategies that 
have shown 3-6 days (27, 50, 51). Longer more controlled release could be achieved 
by using other polymer systems, such as encapsulating the drug within microspheres 
fabricated by the emulsion technique (52, 53). The PLGA/PEG system described 
herein could also be adapted by incorporating the drug into the melt-blend of the 
PLGA/PEG as previously demonstrated, to alter the release profile (16).  
Diclofenac release from scaffolds onto the osteoblast inflammation model was 
performed using a transwell system. This allowed the cell monolayer to be kept 
separate from the scaffold and did not introduce levels of complexity allowing 
migration of cells onto the scaffold. The transwell system allowed drug release into 
the cell culture medium which could freely diffuse through the pores of the 
membrane to the cell monolayer. The system had disadvantages; the scaffold 
swelled as water was imbibed and became constrained by the edges of the 
transwell, possibly affecting release. Nevertheless, as experiments were kept to a 
maximum of 7 days, this effect had little time to come into consequence. Overall, the 
simple system worked successfully to demonstrate that diclofenac sodium release 
from the scaffold remained effective as an anti-inflammatory. An issue that emerged 
as the system developed was adsorption of PGE2 and medium proteins, such as the 
proinflammatory cytokines, to the PLGA/PEG scaffold. This was reflected most 
Page 20 of 39
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review ONLY/ Not for Distribution
obviously in results for PGE2, but may also have been seen in nitrite readings, 
resulting in lower values when scaffolds were present. However, although there were 
differences between groups with and without scaffolds, when comparing scaffolds 
that released diclofenac to scaffolds that were not loaded with any drug, there were 
still significant differences, showing inhibition of the actions of the proinflammatory 
cytokines.  
Effective drug concentration was indicated by cell viability within the osteoblast 
inflammation model. This was important, as anti-inflammatory drugs have been 
shown to induce apoptosis and arrest the cell cycle (54, 55). Achieving a balance 
between mass of drug released to attain effective anti-inflammatory dose and the 
maintenance of cell viability is difficult. The highest scaffold loading of 1000 
µg/scaffold showed almost complete cell death by day 7 of release, a property of the 
large initial burst. This large cell death rendered results of PGE2 and nitrite obsolete, 
as low values only indicated low cell numbers. There was more success with 
scaffolds loaded with 300 µg or 650 µg diclofenac sodium. Results indicate that an 
initial loading between the two would give optimum results for cell viability and 
inhibition of inflammatory markers.  
The in vivo inflammatory environment is vastly different to the one created in this 
study but as an initial validation system, prior to in vivo studies, it was successful.  
Overall, the PLGA/PEG scaffolds released the diclofenac in a profile that would be 
effective for treatment of acute inflammation and the in vitro inflammation model 
demonstrated that diclofenac sodium was effective after release. 
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Figure Legends 
Figure 1: Long term effect of diclofenac sodium on response of primary calvarial 
osteoblasts in proinflammatory cytokine medium. Osteoblasts were cultured for 14 
days in osteogenic medium before experimentation. Cytokines (0.25 ng/mL IL-1β, 
2.5 ng/mL TNF-α, 25 ng/mL IFN-γ) were applied throughout the 27 day period. (A) 
Cell viability, converted to percentage of control medium reading. Values 
represented as mean±SD, n=6. Experiment repeated in triplicate. (B) Cumulative 
nitrite concentration in culture medium at timepoints. Values represented as 
cumulative mean±cumulative SD, n=6. Experiment repeated in triplicate.  (C) PGE2 
concentration in medium at timepoints. Values represented as cumulative 
mean±cumulative SD. Experiment repeated in triplicate. For A, B, C: Statistical 
significance vs. control *(p≤0.01). Statistical significance vs. IL-1β+TNF-α+IFN-γ 
#(p≤0.01). (D) Representative immunocytochemistry images showing expression of 
osteopontin (OPN)/osteocalcin (OCN) and cadherin-11 (cad-11)/collagen-I (col-I) 
after treatment with IL-1β, TNF-α and IFN-γ and diclofenac sodium. Scale bar=90 
µm.  
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Figure 2: PLGA/PEG scaffolds. (A) Representative SEM images of scaffold 
microstructure. (B) Formed and sintered scaffolds showing swelling and degradation 
over 5 weeks. 
Figure 3: Diclofenac sodium release from PLGA/PEG scaffolds. Scaffolds were 
loaded with varying initial concentrations of diclofenac sodium. (A) Cumulative mass 
release of drug over time. (B) Cumulative percentage release of drug over time. 
Values represented by mean of triplicate scaffold release, each measured in 
triplicate, n=9. Error represented by cumulative SD. 
Figure 4: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on cell viability 
in the in vitro calvarial osteoblast inflammation model. Live/Dead™ viability assay of 
osteoblast monolayers after 7 days culture with and without IL-1β, TNF-α and IFN-γ, 
with PLGA/PEG scaffolds initially loaded with various masses of diclofenac sodium. 
(A) Representative images of osteoblast monolayers at day 7, live cells in green and 
dead cells in red. (B) Image quantification performed to determine average number 
of live and dead cells per image. Statistical significance of total cell number vs. total 
cell number in 0 µg/scaffold in osteogenic medium *(p≤0.01). (C) Percentage of live 
cells in each group. Statistical significance vs. 0 µg/scaffold in osteogenic medium 
(**p≤0.001, ***p≤0.0001). Statistical significance vs. 0 µg/scaffold in cytokine 
medium (### p≤0.0001). Experiment repeated in triplicate, each with n=3. 
Figure 5: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on nitrite 
production in the in vitro calvarial osteoblast inflammation model. Nitrite 
accumulation was measured on day 1, 2 and 7, after scaffold placed in transwell. (A) 
Nitrite concentration at each timepoint. (B) Cumulative nitrite concentration over 7 
days. Statistical significance vs. 0 µg/scaffold in osteogenic medium (*p≤0.01). 
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Statistical significance vs. 0 µg/scaffold in cytokine medium (#p≤0.01). Values 
represented as mean±SEM, experiment repeated in triplicate each with n=3. 
Figure 6: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on PGE2 
production in the in vitro calvarial osteoblast inflammation model. PGE2 accumulation 
was measured on day 1, 2 and 7, after scaffold placed in transwell. (A) PGE2 
concentration at each timepoint. (B) Cumulative PGE2 concentration over 7 days. 
Inset shows cumulative PGE2 concentration excluding “no scaffold” groups. 
Statistical significance vs. 0 µg/scaffold in osteogenic medium (*p≤0.01). Statistical 
significance vs. 0 µg/scaffold in cytokine medium (#p≤0.01). Values represented as 
mean±SEM, experiment repeated in triplicate each with n=3. 
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Long term effect of diclofenac sodium on response of primary calvarial osteoblasts in proinflammatory 
cytokine medium. Osteoblasts were cultured for 14 days in osteogenic medium before experimentation. 
Cytokines (0.25 ng/mL IL-1β, 2.5 ng/mL TNF-α, 25 ng/mL IFN-γ) were applied throughout the 27 day 
period. (A) Cell viability, converted to percentage of control medium reading. Values represented as 
mean±SD, n=6. Experiment repeated in triplicate. (B) Cumulative nitrite concentration in culture medium at 
timepoints. Values represented as cumulative mean±cumulative SD, n=6. Experiment repeated in 
triplicate.  (C) PGE2 concentration in medium at timepoints. Values represented as cumulative 
mean±cumulative SD. Experiment repeated in triplicate. For A, B, C: Statistical significance vs. control 
*(p≤0.01). Statistical significance vs. IL-1β+TNF-α+IFN-γ #(p≤0.01). (D) Representative 
immunocytochemistry images showing expression of osteopontin (OPN)/osteocalcin (OCN) and cadherin-11 
(cad-11)/collagen-I (col-I) after treatment with IL-1β, TNF-α and IFN-γ and diclofenac sodium. Scale 
bar=90 µm.  
232x396mm (300 x 300 DPI)  
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Figure 2: PLGA/PEG scaffolds. (A) Representative SEM images of scaffold microstructure. (B) Formed and 
sintered scaffolds showing swelling and degradation over 5 weeks.  
267x330mm (300 x 300 DPI)  
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Figure 3: Diclofenac sodium release from PLGA/PEG scaffolds. Scaffolds were loaded with varying initial 
concentrations of diclofenac sodium. (A) Cumulative mass release of drug over time. (B) Cumulative 
percentage release of drug over time. Values represented by mean of triplicate scaffold release, each 
measured in triplicate, n=9. Error represented by cumulative SD.  
118x161mm (300 x 300 DPI)  
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Effect of diclofenac sodium releasing PLGA/PEG scaffolds on cell viability in the in vitro calvarial osteoblast 
inflammation model. Live/Dead™ viability assay of osteoblast monolayers after 7 days culture with and 
without IL-1β, TNF-α and IFN-γ, with PLGA/PEG scaffolds initially loaded with various masses of diclofenac 
sodium. (A) Representative images of osteoblast monolayers at day 7, live cells in green and dead cells in 
red. (B) Image quantification performed to determine average number of live and dead cells per image. 
Statistical significance of total cell number vs. total cell number in 0 µg/scaffold in osteogenic medium 
*(p≤0.01). (C) Percentage of live cells in each group. Statistical significance vs. 0 µg/scaffold in osteogenic 
medium (**p≤0.001, ***p≤0.0001). Statistical significance vs. 0 µg/scaffold in cytokine medium (### 
p≤0.0001). Experiment repeated in triplicate, each with n=3.  
197x235mm (300 x 300 DPI)  
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Effect of diclofenac sodium releasing PLGA/PEG scaffolds on nitrite production in the in vitro calvarial 
osteoblast inflammation model. Nitrite accumulation was measured on day 1, 2 and 7, after scaffold placed 
in transwell. (A) Nitrite concentration at each timepoint. (B) Cumulative nitrite concentration over 7 days. 
Statistical significance vs. 0 µg/scaffold in osteogenic medium (*p≤0.01). Statistical significance vs. 0 
µg/scaffold in cytokine medium (#p≤0.01). Values represented as mean±SEM, experiment repeated in 
triplicate each with n=3.  
150x169mm (300 x 300 DPI)  
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Effect of diclofenac sodium releasing PLGA/PEG scaffolds on PGE2 production in the in vitro calvarial 
osteoblast inflammation model. PGE2 accumulation was measured on day 1, 2 and 7, after scaffold placed in 
transwell. (A) PGE2 concentration at each timepoint. (B) Cumulative PGE2 concentration over 7 days. Inset 
shows cumulative PGE2 concentration excluding “no scaffold” groups. Statistical significance vs. 0 
µg/scaffold in osteogenic medium (*p≤0.01). Statistical significance vs. 0 µg/scaffold in cytokine medium 
(#p≤0.01). Values represented as mean±SEM, experiment repeated in triplicate each with n=3.  
162x215mm (300 x 300 DPI)  
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Response to Reviewers’ Comments 
Paper Title: Investigation of localised delivery of diclofenac sodium from PLGA/PEG 
scaffolds using an in vitro osteoblast inflammation model. 
Authors: Laura E. Sidney, PhD; Thomas R. J. Heathman, MEng; Emily R. Britchford, MSc; 
Arif Abed, MEng; Cheryl V. Rahman, PhD; Lee D. K. Buttery, PhD. 
 
The authors thank the reviewers for their helpful suggestions to improve the 
manuscript. We have endeavoured to respond to the points raised and make corrections 
to the manuscript where appropriate. 
 
Author’s responses are shown below the Reviewers’ comments. Additions and corrections to 
the manuscript are highlighted yellow. 
 
Reviewers' Comments to Author: 
Reviewer: 1 
General comment: The paper presented by Laura Sidney et al, is a well written. The in vitro 
experiment design is reasonable. The pictures are clear. However, when compared to the 
papers Tissue Engineering Part A published, it is not sound enough. The contents are more 
suitable for material science or pharmaceutical science, since the authors did not perform 
any tissue engineering experiments even in vitro. 
 
Response: Thank you for your comments. The authors acknowledge that within this study, 
no “traditional” tissue engineering experiments were performed. However, we believe that 
the paper is suitable for publication in Tissue Engineering Part A as the PLGA/PEG scaffold 
is intended for a tissue engineering purpose (bone regeneration) with the additional function 
of anti-inflammatory release. Although the study does cover both drug delivery and 
biomaterials science, we consider these to be aspects of the wider tissue engineering field. 
 
Comment 1: No osteogenic experiment was performed when using scaffold as slow release 
system and compared to non-scaffold delivery. The reviewer suggests testing mineralization 
after release diclofenac with PLGA/PEG scaffold (such as Von Kossa or alizarin red 
staining). 
 
Response 1: We acknowledge the referees comment and suggestion.  The cells were cultured 
in osteogenic medium for 14 days prior to being used in these experiments and we have 
shown previously that most effects of cytokines on osteogenic differentiation occur around 
this and earlier stages (Sidney et al., Stem cells and development, 23, 65, 2014).  We 
therefore chose to focus more on these stages rather than the end stage of differentiation and 
the bone nodule assay. Moreover, it is likely to be during the initial phases of exposure that 
effects will be manifest and subsequently carried through to later differentiation, again 
something we have shown previously.  
 
 
Comment 2: As PGE2 signal pathway is very important for bone regeneration and fracture 
healing in vitro and in vivo, suppress this pathway will impair the bone regeneration and 
bone healing. The initial inflammation after tissue injury is essential to initiate tissue repair 
process. 
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Response 2: The authors agree that PGE2, and the enzyme COX-2, play a crucial role in 
fracture healing. This study was designed as a model to show that the system is suitable for 
anti-inflammatory release but we are aware that a non-steroidal anti-inflammatory such as 
diclofenac may not be the most suitable drug, and a steroidal drug, specific COX-2 inhibitor 
or DMARD would be more suitable. Further in vivo testing would be required to investigate 
the long-term effects on fracture healing and unfortunately that is outside the scope of this in 
vitro investigation. The authors agree that the initial inflammation after tissue injury is 
crucial, and a balance would need to be sought between anti-inflammatory action to prevent 
capsule formation due to foreign body implantation, and the ability of the scaffold to assist 
bone regeneration.    
 
Addition to manuscript: To clarify the point the reviewer made, we have added a short 
section to the discussion of the manuscript (page 17, paragraph 2) highlighting that PGE2 also 
plays a role in fracture healing, alongside inflammation. 
 
Comment 3: The PLGA/PEG scaffold the authors investigated is widely studied.  
 
Response 3: One of the advantages of this study is that the PLGA/PEG formulation scaffold 
has already been established as suitable for bone regeneration, as discussed in the manuscript. 
However, this will be the first paper that describes the release of anti-inflammatory drugs 
from this system. 
 
Comment 4: The use of NSAIDs -diclofenac sodium is still controversial. Long term 
treatment could impair bone fracture healing, while short term treatment did not affect 
fracture healing, but do not enhance fracture healing either, therefore showing no beneficial 
effect (Krischack GD, Arch Orthop Trauma Surg. 2007 Jan;127(1):3-9. Epub 2006 Jul 25). 
 
Response 4: The authors agree with the reviewer that there is a lot of contradictory evidence 
showing the effects of NSAID treatment on fracture healing. We believe this study is an 
example of short term treatment, as although the scaffold does release drug for over 60 days, 
over 80% of release occurs within the first 4 days. The remaining drug is released at a state of 
about 0.2% per day. For the scaffold loaded with 650 µg drug this would be 1.3 µg per day. 
The authors do not know whether this concentration would have an effect on the local 
environment in vivo, but it is considerably below the dose administered per day in the 
publication stated. Assuming that this study can be considered short term administration, the 
fact that bone healing may not be adversely effected in the long-term, is a positive outcome. 
The addition of an anti-inflammatory drug was not intended to enhance fracture healing 
outside of the positive effect of the scaffold, but was envisioned to prevent any foreign body 
reaction or adverse inflammation upon implantation. As discussed above, diclofenac sodium 
or NSAIDs may not be the most suitable drugs for release in vivo but the system could be 
adapted to investigate drugs with alternative mechanisms of action. 
 
Comment 5: The reviewer thought the way the authors modified the data in Figure 6 by 
removing a comparison group was not appropriate. If looked at Figure 5, the use of scaffold 
also decreased the NO although the reviewer not sure there is a statistic difference. This 
might not be caused by the absorption of PGE2, rather than absorption of IL-1β, TNFα and 
IFN-γ since they are proteins. 
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Response 6: The authors understand the reservations the reviewer has about the 
modifications of the data in Figure 6. However, the experiments could have as easily been 
performed without the “no scaffold” control and the important comparison in this study is the 
effect of the drug releasing scaffold in contrast to the no drug releasing scaffold. The “no 
scaffold” control was included to show the effect adding a scaffold had on the inflammatory 
model.  It can be concluded that adding a scaffold changes the model by presenting a surface 
on which proteins can adsorb, including both the PGE2 and proinflammatory cytokines. 
However, the model is still valid as a significant difference in PGE2 is seen between scaffolds 
releasing diclofenac and non-releasing scaffolds. In figure 5, the scaffold group does have 
slightly lowered NO readings but this decrease is not significant. Due to this, the authors 
came to the conclusion that it is predominantly PGE2 adsorption to the scaffold affecting 
results, but this may also be contributed to by cytokine adsorption to the scaffold. We have 
adjusted the presentation of the figure so that it shows PGE2 release of all groups at each 
timepoint and as cumulative release, we have included an inset graph of the cumulative data 
without the “no scaffold” control to demonstrate that there is a reduction in the levels of 
PGE2 when diclofenac is released. 
 
Adjustment to manuscript:  Figure 6 has been adjusted to include cumulative release with 
all data points. The results sections for figure 6 has been adjusted to explain this (page 15, 
paragraph 1) and a section added to the discussion to acknowledge that there were differences 
in the inflammation model when a scaffold was added (page 19, paragraph 3). 
 
Comment 6: Histogram in Figure 1 and 4 should be bigger for better viewing. Figure 1A 
should be indicated whether there are statistic differences between treatment and control 
groups regarding cell viability. 
 
Adjustment to manuscript: Both figure 1 and figure 4 have been adjusted to enlarge the 
histograms. Figure 1A has been adjusted to indicate the statistical differences between treated 
and control groups in terms of cell viability. 
  
Comment 7: Please do not use asterisk in control groups in histogram since the comparisons 
are always compared to control group and/or different treatment group. It is confusing to 
read. 
 
Adjustment to manuscript: Asterisks on control groups have been removed from figure 1, 
figure 4, figure 5 and figure 6. 
 
 
Reviewer: 2  
 
General comments: This is a well organized and described study with a well supported 
rationale, detailed experimental plan with appropriate statistics throughout and the 
conclusions are supported by the results. A few minor comments follow. 
 
Comment 1: In abstract - it would be nice to provide some indication of the magnitude of 
changes in most important cell parameters to make the abstract more 
informative/quantitative. This is important since the abstract is usually the first and often the 
only part of a manuscript read/available. Incorporating quantitative data will make the 
abstract more informative and better highlight the technical merits of the work for readers. 
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Adjustment to manuscript: We thank the reviewer for their helpful comments. The abstract 
(pg 3) has now been adjusted to include some quantitative data about the cell parameters 
were affected by the introduction of the proinflammatory cytokines and the drug-releasing 
scaffolds, in terms of cell viability, NO production and PGE2 production. 
 
Comment 2: In the discussion section, it might be appropriate to comment on potential 
effects/role of diclofenac on macrophages/neutrophils since these cells are also critical to the 
inflammatory response - and in particular how diclofenac may influence macrophage 
phenotype (M1 vs M2). 
 
Response 2: Diclofenac sodium release would almost certainly have an effect on the 
presence and role of neutrophils and macrophages. However, the effect of this in bone 
regeneration is unclear as previous studies have indicated that an absence of neutrophils and 
macrophages have little effect on fracture healing, due to crossover of signalling between the 
inflammatory cells and the native bone cells. As the effect of diclofenac on inflammatory 
cells is of importance we have added a section to the discussion detailing the possible 
ramifications of diclofenac sodium release on macrophages and neutrophils. 
 
Adjustment to manuscript: A section detailing the effect of diclofenac on neutrophil 
recruitment and macrophage activation has been added to the discussion on page 16, 
paragraph 2. 
 
Page 41 of 39
Mary Ann Liebert, Inc.,140 Huguenot Street, New Rochelle, NY 10801
Tissue Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
